Gene Overdosage and comorbidities during the early lifetime in Down Syndrome

Explore

News & Events

More news
3 April 2025

Final General Assembly in Munich

We are excited to welcome the entire consortium for the final GO-DS21 General Assembly in Munich, Germany, from 6-8 May 2025. The meeting will start with a networking dinner at the Mercure Hotel Munich Airport on Tuesday, May 6th. On Wednesday morning, May 7th, attendees will be shuttled to the Helmholtz Institute for a full-day meeting. On Thursday, May 8th, the meeting will end at 3:30 pm at the Helmholtz Institute. Please register here for the hybrid meeting, either for face-to-face attendance or for online participation.

News & Events

More news
3 April 2025

Final General Assembly in Munich

We are excited to welcome the entire consortium for the final GO-DS21 General Assembly in Munich, Germany, from 6-8 May 2025. The meeting will start with a networking dinner at the Mercure Hotel Munich Airport on Tuesday, May 6th. On Wednesday morning, May 7th, attendees will be shuttled to the Helmholtz Institute for a full-day meeting. On Thursday, May 8th, the meeting will end at 3:30 pm at the Helmholtz Institute. Please register here for the hybrid meeting, either for face-to-face attendance or for online participation.

Summary Statement

Clinicians, pathophysiologists, integrative bioinformaticians and artificial intelligence computer scientists working to unravel intrinsic and extrinsic mechanisms that impact on Down Syndrome (DS) comorbidity (focusing on obesity and intellectual disability. The examination of the pathways and mechanisms involved in comorbidities and multi-morbidities that induce the coexistence of two or more diseases in an individual is of major importance for the effective treatment of patients suffering from DS, obesity and mental disorders.

To achieve a system view to this disease we will integrate multiple datasets using new multi-layered approaches, which offer a unique opportunity for the integration and synthesis of molecular (multi-OMICS) preclinical (cellular and animal) and clinical datasets and metadata (environment, patient history) to understand the mechanisms of comorbidities.

In GO-DS21 we plan to use publicly available and self-developed bioinformatics tools, network science, statistical machine learning software and mathematical modeling approaches to unravel the shared etiological mechanisms in DS and the associated comorbidities, mainly obesity and intellectual disability.

Learn More

Our vision

Learn more

Why it matters

Learn more
X (Twitter)
YouTube
LinkedIn